Cardiovascular Risk Estimation and Eligibility for Statins in Primary Prevention Comparing Different Strategies

被引:12
|
作者
Nanchen, David [1 ,2 ]
Chiolero, Arnaud [2 ]
Cornuz, Jacques [1 ]
Marques-Vidal, Pedro-Manuel [2 ]
Firmann, Mathieu [3 ]
Mooser, Vincent [4 ]
Paccaud, Fred [2 ]
Waeber, Gerard [3 ]
Vollenweider, Peter [3 ]
Rodondi, Nicolas [1 ]
机构
[1] Univ Lausanne, Univ Hosp Ctr, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[2] Univ Lausanne, Univ Hosp Ctr, Inst Social & Prevent Med, Lausanne, Switzerland
[3] Univ Lausanne, Univ Hosp Ctr, Dept Med, Lausanne, Switzerland
[4] GlaxoSmithKline, Div Genet, King Of Prussia, PA USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2009年 / 103卷 / 08期
关键词
CORONARY-HEART-DISEASE; EUROPEAN GUIDELINES; FRAMINGHAM; POPULATION; THERAPY; SCORE; EPIDEMIOLOGY; PARTICIPANTS; METAANALYSIS; MORTALITY;
D O I
10.1016/j.amjcard.2008.12.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recommendations for statin use for primary prevention of coronary heart disease (CHID) are based on estimation of the 10-year CHD risk. It is unclear which risk algorithm and guidelines should be used in European populations. Using data from a population-based study in Switzerland, we first assessed 10-year CHD risk and eligibility for statins in 5,683 women and men 35 to 75 years of age without cardiovascular disease by comparing recommendations by the European Society of Cardiology without and with extrapolation of risk to age 60 years, the International Atherosclerosis Society, and the US Adult Treatment Panel III. The proportions of participants classified as high-risk for CHD were 12.5% (15.4% with extrapolation), 3.0%, and 5.8%, respectively. Proportions of participants eligible for statins were 9.2% (11.6% with extrapolation), 13.7%, and 16.7%, respectively. Assuming full compliance to each guideline, expected relative decreases in CHD deaths in Switzerland over a 10-year period would be 16.4% (17.5% with extrapolation), 18.7%, and 19.3%, respectively; the corresponding numbers needed to treat to prevent 1 CHD death would be 285 (340 with extrapolation), 380, and 440, respectively. In conclusion, the proportion of subjects classified as high risk for CHD varied over a fivefold range across recommendations. Following the International Atherosclerosis Society and the Adult Treatment Panel III recommendations might prevent more CHD deaths at the cost of higher numbers needed to treat compared with European Society of Cardiology guidelines. (C) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:1089-1095)
引用
收藏
页码:1089 / 1095
页数:7
相关论文
共 50 条
  • [31] Dietary strategies for cardiovascular disease risk factors prevention
    Mazur, Michal
    Przytula, Agata
    Szymanska, Magdalena
    Popiolek-Kalisz, Joanna
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (09)
  • [32] Risk factors for cardiovascular diseases: the focus on primary prevention
    Wolska, Magdalena
    Peruzzi, Mariangela
    Kazirod-wolski, Karol
    Wrobel, Pawel
    Oles, Izabela
    Sielski, Janusz
    Jankowski, Piotr
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2023,
  • [33] Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes
    Chan, Juliana C. N.
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (04) : 344 - 346
  • [34] Effectiveness of statins for the primary prevention of cardiovascular disease in the Asian elderly population
    Lin, Yu-Wen
    Wang, Chi-Chuan
    Wu, Chau-Chung
    Hsu, Yih-Ting
    Lin, Fang-Ju
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 373 : 25 - 32
  • [35] Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies
    Barbagelata, Leandro
    Masson, Walter
    Rossi, Emiliano
    Lee, Martin
    Lagoria, Juan
    Vilas, Manuel
    Pizarro, Rodolfo
    Rosa Diez, Guillermo
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2022, 29 (05) : 435 - 443
  • [36] Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
    Tonelli, Marcello
    Lloyd, Anita
    Clement, Fiona
    Conly, Jon
    Husereau, Don
    Hemmelgarn, Brenda
    Klarenbach, Scott
    McAlister, Finlay A.
    Wiebe, Natasha
    Manns, Braden
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (16) : E1189 - E1202
  • [37] Identification of effective screening strategies for cardiovascular disease prevention in a developing country: using cardiovascular risk-estimation and risk-reduction tools for policy recommendations
    Selvarajah, Sharmini
    Haniff, Jamaiyah
    Kaur, Gurpreet
    Hiong, Tee Guat
    Bujang, Adam
    Cheong, Kee Chee
    Bots, Michiel L.
    BMC CARDIOVASCULAR DISORDERS, 2013, 13
  • [38] Statins for primary prevention of cardiovascular disease Are not needed for people at very low risk and should be tailored to individual risk in everyone else
    Deckers, Jaap W.
    Blumenthal, Roger S.
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 342
  • [39] Barriers to cardiovascular disease risk scoring and primary prevention in Europe
    Hobbs, F. D. R.
    Jukema, J. W.
    Da Silva, P. M.
    McCormack, T.
    Catapano, A. L.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (10) : 727 - 739
  • [40] OVERVIEW OF RISK-ESTIMATION TOOLS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES IN EUROPEAN POPULATIONS
    Gorenoi, Vitali
    Hagen, Anja
    CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2015, 23 (02) : 91 - 99